Biopharmaceutical Contract Manufacturing Market

Market Size

The global biopharmaceutical contract manufacturing market, valued at USD 28.0 billion in 2025, is projected to reach USD 31.0 billion in 2026 and USD 63.9 billion by 2035, with a CAGR of 8.3% during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

• The increased extent of outsourcing by large pharma companies, enhanced demand for complex biopharmaceuticals and personalized medicine, and the need for specialized expertise is driving the demand for biologics contract manufacturing operations.
• In terms of type of service offered, the drug substance (API) manufacturing segment secures ~60% of the overall revenue share, owing to the increasing interest in API outsourcing fueled by lower investment costs, easier access to cutting-edge technologies, and more efficient resource utilization.
• In terms of the type of biologic manufactured, antibodies capture the highest share (~60%) of the market; this is due to their dominance in treating several diseases such as cancer, autoimmune disorders, infectious diseases, and rare diseases.
• In terms of type of expression system used, mammalian expression systems currently hold around 80% of the market share, due to their superior ability to produce complex proteins by mimicking human biology.
• In terms of scale of operation, commercial scale segment captures around 90% of the overall biopharmaceutical contract manufacturing market share; in the coming years, clinical scale segment is likely to grow at a relatively faster pace owing to the increasing number of clinical trials and the growing focus on personalized medicines.

• Based on the therapeutic area, oncological disorders segment captures largest share (~35%) of the market; this surge in demand is due to their high prevalence, complex treatment needs, and the dominance of biologics like monoclonal antibodies in cancer therapies.
• With respect to company size, the large / very large companies dominate the current market (~60%) due to their established presence and known expertise in the market.
• In terms of key geographical regions, Asia-Pacific holds around 40% of the market share; this can be attributed to the fact that the number of manufacturing facilities in this region is relatively higher when compared to other regions.

Market Overview

Biopharmaceuticals are the medicinal / therapeutic products that are either manufactured using living organisms or semi-synthesized from biological sources. These macromolecules, with molecular weights often exceeding 1,000 daltons, often defy the conventional chemical synthesis methods, compelling industry players to invest in advanced biotech platforms for scalable production of biopharmaceuticals.

The rising prevalence of chronic diseases and shift towards advanced therapeutic modalities have significantly boosted demand for biologics. Consequently, numerous developers outsource manufacturing operations to third-party providers, enabling them to meet escalating needs of the industry. Notably, outsourcing business operations to third party developers and manufacturers provides excellent opportunities to access greater production capabilities and / or new products. 

Further, analytical testing, toxicity testing and fill / finish operations, are among the most commonly outsourced operations. Moreover, the demand for biopharmaceutical and pharmaceutical contract manufacturing, as well as downstream process development is on the rise. To exploit this demand and attract more clients, the smaller service provider companies are expanding their capabilities and / or partnering with other players in order to expand their offerings.

With outsourcing becoming increasingly accepted as a viable and beneficial business model within this field, the global market for biopharmaceutical contract manufacturing will witness remarkable growth during the forecast period.

Recent Developments

• Partnership and Collaborations: Contract manufacturers engaged in this domain have forged several partnerships with other stakeholders to enhance their portfolios, significantly influencing innovation and global reach. Notably, manufacturing agreements emerged as the most (17%) popular type of partnership model adopted by players engaged in this domain. This is due to the incessant efforts of players to further advance the development of their biologic product offerings, across different development phases.
• Increasing Funding and Investments: Over the years, monetary assistance from venture capitalists and funding schemes of various public and private organizations, along with assistance from regulatory authorities, have allowed start-ups / small companies to progress their research and development efforts. Maximum number of funding instances in this domain were reported in first half of 2024. This is due to the enhanced pipeline of biopharmaceuticals including ADCs, cell / gene therapies and GLP-1 drugs, ultimately leading to an overall increase in outsourcing of biopharmaceutical manufacturing.
• Mergers and Acquisitions: The market analysis shows several mergers and acquisitions, which are likely to drive the growth in this market. Such deals help the companies in gaining additional capability to offer a wider range of products and services, integrate new technologies and gain access to new markets or customer segments. For instance, Tourmaline Bio (US) was acquired by Novartis (Switzerland) in October 2025.
• Biopharmaceutical CMOs Expanding their Global Reach: In recent years, biopharmaceutical contract manufacturing industry has shown a notable increase in the number of players expanding their facilities in order to increase their global reach and / or gain additional expertise. A prime example of this trend is Agilent Technologies opening a new biologics facility in India.
• Demand of Commercial Scale Outsourcing Operations Growing at a Higher CAGR: The upsurge in the demand of commercial scale outsourcing operations is due to the fact that several biopharmaceuticals are still in the preclinical and clinical stages of development. These biopharmaceuticals will receive market approval in the coming years, prompting developers to outsource their manufacturing operations. 
• Global Pharmaceutical Contract Production Capacity is Spread across Various Geographies: Several factors, including globalization and introduction of political and regulatory reforms, have helped in expanding advanced contract manufacturing services for biopharmaceuticals beyond developed geographies alone. Currently, several players in emerging geographies, such as those based in Asia-Pacific, offer high quality contract manufacturing services for biopharmaceuticals, along with providing lucrative cost benefits. 
   

Industry Experts on Biopharmaceutical Contract Manufacturing Market

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:

• Chief Executive Officer, Mid-Sized Company, Scotland
• Chief Executive Officer and Co-Founder, Small Company, Slovenia
• Former Chief Technical Officer, Large Company, US
• President, Mid-Sized Company, China
• Former Senior Director of Global Strategic Marketing, Large Company, US
• Former Senior Director of Commercial Strategy and Market Insights, Large Company, US
• Former Global Head of Sales and Marketing and Head of Business Development, Large Company, US
• Business Development Manager, Small Company, Spain
• Manager Marketing and Sales, Mid-Sized Company, Germany

Biopharmaceutical contract manufacturing domain will mark a turning point in the coming future. Former Senior Director of Commercial Strategy and Market Insights, Large Company, US, “According to me, the most significant advancement is for monoclonal antibodies, and protein or peptide-based therapies, for which the trend is shifting towards continuous manufacturing. On the other hand, for cell therapies, the transformation revolves around increased level of automation in the manufacturing processes and transition from autologous to allogeneic cell therapies. For gene therapies, the shift the rare diseases towards larger target indications will have a significant impact on its scale of manufacturing. Likewise, for nucleic acids, the emphasis should be on diversifying from infectious diseases and seeking breakthroughs in addressing other medical conditions”.

Market Drivers

• Access to Advanced Technologies: A key strength of the biopharmaceutical contract manufacturing industry lies in providing biotech firms with seamless access to cutting-edge bioprocessing technologies, such as single-use bioreactors, continuous perfusion processes, and AI-driven automation, without requiring substantial capital investments for in-house facilities. Further, these specialized CMOs invest heavily in next-generation infrastructure, providing technical edge that enhances yield, reduce contamination risks, enable faster scalability, and improve efficiency in biopharmaceuticals production.
• Operational Flexibility and Cost Efficiency: The operational flexibility provided by contract manufacturing organizations enables biopharmaceutical companies to cater to the increased demand for products by optimizing manufacturing processes at various scales and handling unforeseen challenges more effectively. Further, the outsourcing of operations significantly helps companies to reduce the overall cost associated with drug manufacturing, thereby allowing them to focus their resources on research and development of products.

Paradigm Shift Towards Continuous Bioprocessing

One very recent and innovative development in the biopharmaceutical contract manufacturing market is the accelerating shift towards continuous and intensified bioprocessing. Notably, this technique is rapidly transitioning from an emerging innovation in 2025, to a standard practice in 2026. This shift is primarily due to the fact that continuous bioprocessing techniques help in addressing intensifying pricing pressures by boosting productivity and reducing costs for production of complex biopharmaceuticals and advanced therapies. 

Recently, Enzene Biosciences, a subsidiary of Alkem Laboratories, has fully implemented its EnzeneX™ platform; it is the world's first validated fully-connected continuous manufacturing (FCCM™) technology for commercial biopharmaceuticals production. This innovation allows for end-to-end continuous processing of monoclonal antibodies and other biologics, significantly reducing production timelines and overall manufacturing costs, when compared to traditional batch methods.

Companies Expanding Local Presence in the US - Is it Driven by Tariffs?

Many biopharmaceutical contract manufacturing organizations developing biopharmaceuticals such as, vaccines, antibodies, and cell and gene therapies, are building / expanding their manufacturing facilities right in the US. This is likely being done in order to avoid President Trump's high tariffs on imported pharmaceutical products and supplies from places like China, Canada, or Mexico, which can add up to 100% extra costs.

Recently, in January 2026, Samsung Biologics entered into an agreement with GSK in order to acquire its Human Genome Sciences facility located in Rockville, Maryland. Through this agreement, the company marks its presence in the US biopharma manufacturing market. Additionally, in May 2025, Taiwan-based company, Bora Biologics, announced the expansion of its US FDA-registered commercial manufacturing facility in San Diego, US.

Market Segmentation Analysis

Manufacturing in Mammalian Expression Systems is Most Widely Outsourced to Biopharmaceutical Contract Manufacturing Organizations

• In 2026, mammalian expression systems hold >80% of the overall market share. This is primarily because of their human-like environment for protein processing, high yield and scalability, and proven safety across several biopharmaceuticals.
• Mammalian expression systems segment is likely to grow at a relatively faster pace, with a CAGR of 8.6%, during the forecast period.

Antibodies Lead the Biopharmaceutical Contract Manufacturing Market with Unparalleled Demand

• According to the biopharmaceutical contract manufacturing market forecast, the antibodies segment accounts for ~60% of the overall market revenue. This high share can stem from their immense use across several therapeutic areas, such as oncological disorders, autoimmune disorders, infectious diseases, and rare diseases.
• In future, the cell therapies segment is likely to have high biopharmaceutical contract manufacturing market growth during the forecast period.

Market Regional Insights

Asia-Pacific Dominates the Biopharmaceutical Contract Manufacturing Domain

Asia-Pacific is dominating the market for biopharmaceutical contract manufacturing domain, securing ~40% of the overall revenue share. This is due to the presence of affordable labor and raw materials, along with lower facility construction costs within the region. 

China Biopharmaceutical Contract Manufacturing Market

China dominates the biopharmaceutical contract manufacturing market, driven by the fact that it leads Asia-Pacific in terms of capacity and expertise dedicated to innovative products and services, particularly in monoclonal antibodies and biosimilars. Massive government investments under initiatives like Healthy China 2030 fuel this growth; they prioritize biopharma infrastructure and deliver cost advantages far lower than those in Western markets, thereby attracting global outsourcing. 

Adoption of Biopharmaceutical Contract Manufacturing Services in Asia-Pacific

Asia-Pacific is the fastest growing region, as per our biopharmaceutical contract manufacturing market analysis. Rapid expansion of biopharmaceutical production capacities in countries like China and South Korea accompanied by the widespread adoption of advanced manufacturing technologies is driving the growth of market in these countries. Notably, South Korea based Samsung Biologics has been expanding its biopharmaceuticals manufacturing capacity with opening of several new facilities. In April 2025, the company announced opening of a new biopharmaceuticals manufacturing plant, which resulted in the total capacity of the company to be 784 kL.  

Biopharmaceutical Contract Manufacturing Market: Scope of the Report

Key Report Attributes	Details
Historical Trend	Since 2022
Forecast Period	Till 2035
Market Size 2026	USD 31.0 Billion
Market Size 2035	USD 63.9 Billion
CAGR (till 2035)	8.3%
Key Players Profiled	AbbVie Agilent Technologies Boehringer Ingelheim Catalent Cipla Eurofins Fresenius Kabi Lonza Novartis Sandoz WACKER WuXi Biologics (A complete list of companies captured is available in the report)
Segments Covered	Type of Service Offered Type of Biologic Manufactured Type of Expression System Used Scale of Operation Therapeutic Area Company Size Key Geographical Regions
Excel Data Packs (Complimentary)	Market Landscape Regional Capability Analysis Partnerships and Collaborations Funding and Investments Mergers and Acquisitions Recent Expansions Big Pharma Initiatives Capacity Analysis Demand Analysis Total Cost of Ownership Market Forecast and Opportunity Analysis
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization

Market Segments

Based on the research, we have segmented the biopharmaceutical contract manufacturing market into type of service offered, type of biologic manufactured, type of expression system used, scale of operation, therapeutic area, company size and key geographical regions.

By Type of Service Offered

• Drug Substance (API) Manufacturing
• Drug Product (FDF) Manufacturing

By Type of Biologic Manufactured

• Antibodies
• Proteins / Peptides
• Vaccines
• Cell Therapies
• Gene Therapies
• Other Biologics

By Type of Expression System Used

• Mammalian Expression Systems
• Microbial Expression Systems
• Other Expression Systems

By Scale of Operation

• Preclinical / Clinical Scale
• Commercial Scale

By Therapeutic Area

• Oncological Disorders
• Cardiovascular Disorders
• Metabolic Disorders
• Infectious Diseases
• Autoimmune Disorders
• Neurological Disorders
• Genetic Disorders
• Other Disorders

By Company Size

• Small Companies
• Mid-sized Companies
• Large and Very Large Companies

By Key Geographical Regions

• North America
  • US
  • Canada
  • Puerto Rico
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia-Pacific
  • China
  • South Korea
  • Japan
  • Singapore
  • Rest of the Asia-Pacific
• Rest of the World
  • Israel
  • Argentina
  • Africa

Frequently Asked Questions

Question 1: What is a CDMO in biopharmaceuticals?

Answer: A CDMO in biopharmaceuticals is a specialized contract development and manufacturing organization that provides end-to-end services, from cell line development and process optimization to GMP production and regulatory support.

Question 2: How big is the biopharmaceutical contract manufacturing market?

Answer: The market size is anticipated to be worth USD 31.0 billion in 2026.

Question 3: What is the anticipated CAGR of biopharmaceutical contract manufacturing market?

Answer: The global market is estimated to grow at an annualized CAGR of 8.3% during the forecast period.

Question 4: Which region is expected to witness the highest growth rate in biopharmaceutical contract manufacturing market?

Answer: Asia-Pacific is likely to be the fastest growing market segment with a CAGR of 9.9%.

Question 5: Which segment, in terms of scale of operation currently accounts for the largest share of the biopharmaceutical contract manufacturing industry?

Answer: The commercial scale segment currently holds the largest market share (~90%).

Question 6: Who are the biggest biopharmaceutical contract manufacturers?

Answer: AbbVie, Agilent Technologies, Boehringer Ingelheim, Catalent, Cipla, Eurofins, Fresenius Kabi, Lonza, Novartis, Sandoz, WACKER and WuXi Biologics.